Stockscreener 앱 받기
0.4205
0.12%
0.0005
시간 외 거래:
.40
-0.0205
-4.88%
Reshape Lifesciences Inc 주식(RSLS)의 최신 뉴스
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerALBT, NDOI, DNB, RSLS - The Malaysian Reserve
ReShape Lifesciences (RSLS) Secures Patent for Innovative Intrag - GuruFocus
ReShape Lifesciences (RSLS) Showcases Promising Diabetes Device at Neuromodulation Event | RSLS Stock News - GuruFocus
ReShape Lifesciences® Presents Pre-clinical Data on Its - GlobeNewswire
Breakthrough Diabetes Treatment: New Neuromodulation Device Eliminates Need for Insulin Injections - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – ALBT, NDOI, DNB, RSLS - GlobeNewswire Inc.
The Psychology of ReShape Lifesciences Inc Inc. (RSLS) Price Performance: Understanding Market Sentiment - investchronicle.com
There is no way ReShape Lifesciences Inc (RSLS) can keep these numbers up - Sete News
Market Resilience: ReShape Lifesciences Inc (RSLS) Finishes Weak at 0.36, Down -0.85 - DWinneX
Checking in on ReShape Lifesciences Inc (RSLS) after recent insiders movement - knoxdaily.com
Closing Figures Unveiled: ReShape Lifesciences Inc (RSLS) Drop -12.17, Closes at 0.39 - DWinneX
ReShape Lifesciences amends asset purchase terms with Ninjour By Investing.com - Investing.com India
ReShape Lifesciences secures patent for intragastric balloon By Investing.com - Investing.com Canada
ReShape Lifesciences amends asset purchase terms with Ninjour - Investing.com
ReShape Lifesciences (RSLS) Advances with New Patent for Intraga - GuruFocus
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System - The Manila Times
Revolutionary Weight Loss Tech: ReShape's New Patent Protects Self-Deflating Gastric Balloon Innovation - Stock Titan
ReShape Lifesciences Inc (RSLS)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Press Release Distribution & PR Platform - ACCESS Newswire
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update - The Globe and Mail
Insider Sale Alert: ReShape Lifesciences Inc [RSLS] – Is it Time to sell? - knoxdaily.com
ReShape Lifesciences skyrockets after receiving U.S. patent for diabetes neuromodulation technology - MSN
ReShape Lifesciences Ignites Retail Frenzy As Stock Soars On US Patent For Diabetes Neuromodulation System - Asianet Newsable
ReShape Shares Soar After USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences secures patent for diabetes treatment By Investing.com - Investing.com South Africa
ReShape Lifesciences Gets USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences (RSLS) Gains on Diabetes Neuromodulation Patent News - GuruFocus
ReShape Lifesciences secures patent for diabetes treatment - Investing.com
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - The Manila Times
ReShape Lifesciences® Secures Patent for Innovative Vagal Neuromodulation Device to Treat Type 2 Diabetes with Enhanced Energy Efficiency - Nasdaq
ReShape Lifesciences® Receives Notice of Allowance for - GlobeNewswire
Revolutionary Diabetes Treatment Patent: ReShape's New Tech Uses 90% Less Energy Than Current Solutions - Stock Titan
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Why Did ReShape Lifesciences Plunge 11.04%? Earnings Miss, Bearish Sentiment - AInvest
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop - Investing.com UK
Reshape Lifesciences Stock Price, Quotes and Forecasts | NASDAQ:RSLS - Benzinga
ReShape Lifesciences Reports 2024 Financial Results and Strategic Updates - TipRanks
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop By Investing.com - Investing.com South Africa
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
ReShape Lifesciences Shares Surge 82.2% After Partnership Announcement - AInvest
Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga
Penny Stock ReShape To Distribute FDA-Cleared Neuromuscular Device In US - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket - Benzinga
ReShape secures exclusive deal for neuromuscular rehab tech By Investing.com - Investing.com India
ReShape Lifesciences to Bring Motion Informatics' Neuromuscular Rehabilitation Devices to US - MarketScreener
ReShape secures exclusive deal for neuromuscular rehab tech - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market - The Manila Times
ReShape Lifesciences® Partners with Motion Informatics to - GlobeNewswire
AI Breakthrough: ReShape Brings Next-Gen Neuro Rehabilitation Platform to US Healthcare - Stock Titan
RSLS stock touches 52-week low at $0.34 amid market challenges - Investing.com India
11.62%
0.20%
자본화:
|
볼륨(24시간):